

2022 ISV ANNUAL CONGRESS ORAL PROGRAM

SUNDAY 18 SEPTEMBER 2022

08:00-10:00	REGISTRATION
08:00-10:00	WELCOME COFFEE Sponsored by EuBiologics Co.
10:00-10:10	ISV CONGRESS OPENING SESSION: CO-CHAIR REMARKS (5 min) Joon Haeng Rhee, <i>Chonnam National University</i> ; Manon Cox, <i>NextWaveBio</i> ; Gary Kobinger, <i>University of Texas Medical Branch (UTMB)</i> WELCOME BY ISV PRESIDENT (3 min) - Denise Doolan, <i>James Cook University</i>
10:10-11:55	KEYNOTE SESSION: HOT TOPICS IN 21 st CENTURY VACCINES SESSION CHAIRS: Manon Cox, <i>NextWaveBio</i> and Joon Haeng Rhee, <i>Chonnam National University</i>
10:10-10:45	KEYNOTE SPEAKER - Bali Pulendran, <i>Stanford University</i> Systems Vaccinology
10:45-11:20	KEYNOTE SPEAKER – Ann Ginsberg, <i>The Bill & Melinda Gates Foundation</i> End-to-End TB Vaccine Development to End TB
11:20-11:55	KEYNOTE SPEAKER - Hiroshi Kiyono, <i>University of Tokyo</i> Mucosal Vaccine: Bringing the Old Wisdom to Reality
12:00-13:30	LUNCH Sponsored by VGXI, Inc.
13:30-15:20	PLENARY SESSION 1: COVID-19 VACCINES PART 1 SESSION CHAIRS: Jeffrey Ulmer, <i>TechImmune LLC</i> and Margaret Liu, <i>ProTherImmune</i>
13:30-13:55	Vectored Viral Vaccine Candidates for SARS-CoV-2 Amy Espeseth, <i>Merck</i>
13:55-14:20	Differentiation of Memory T Cells Elicited by COVID-19 Vaccines Eui-Cheol Shin, <i>Korea Advanced Institute of Science and Technology (KAIST)</i>
14:20-14:35	What Vaccine-Induced Immune Responses Control Breakthrough COVID-19? Stephen Kent, <i>University of Melbourne</i>
14:35-14:50	Next Generation Multivalent COVID-19 DNA Vaccine Makutiro Masavuli, <i>The University of Adelaide</i>
14:50-15:05	Characterization of Humoral Immune Responses to an Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice Mariam Maltseva, <i>University of Ottawa</i>
15:05-15:20	Robust Immunogenicity and Full Efficacy Against SARS-CoV-2 in Mice, Hamsters and Rhesus macaques of a COVID-19 Vaccine Candidate Based on an MVA Vector Expressing the SARS-CoV-2 S Protein Juan García-Arriaza, <i>Centro Nacional de Biotecnología</i>
Pre-Recorded	Elicitation of Long-Lived Plasma Cells Following SARS-CoV-2 Spike Vaccination Madhu Prabhakaran, <i>Vaccine Research Center, NIAID, National Institutes of Health</i>
15:30-16:00	COFFEE BREAK Sponsored by Moderna
16:00-17:50	PLENARY SESSION 2: VACCINE DESIGN AND ADJUVANT SESSION CHAIRS: David Weiner, <i>The Wistar Institute</i> and Sanjay Phogat, <i>GSK</i>
16:00-16:25	Particulate Adjuvant Strategies for Cancer Vaccines Ed Lavelle, <i>Trinity College Dublin</i>
16:25-16:50	Vaccine Adjuvant and Production Technologies and Biomanufacturing Resilience in Canada Lakshmi Krishnan, <i>National Research Council Canada</i>
16:50-17:05	A Novel Draining Lymph Node Targeting CpG Oligonucleotide, S-540956 is a Potent Adjuvant When Used with HSV-2 Glycoprotein D and Controls Recurrent Genital Herpes Sita Awasthi, <i>University of Pennsylvania</i>
17:05-17:20	Deimmunized Flagellin as a Mucosal Vaccine Adjuvant Shee Eun Lee, <i>Chonnam National University</i>
17:20-17:35	The Novel Adjuvant, ADA-1, Restores Age-Associated Defects in the Adaptive Immune Response to <i>Clostridioides Difficile</i> Infection and Vaccination in an Aging Mouse Model Michele Kutzler, <i>Drexel University</i>
17:35-17:50	In Vivo Delivery of Engineered Synthetic DNA-Encoded SARS-CoV-2 Monoclonal Antibodies and Preventative Efficacy in Non-Human Primates Ami Patel, <i>The Wistar Institute</i>
18:00-19:00	POSTER SESSION # 1
18:00-20:00	WELCOME RECEPTION Sponsored by EpiVax

MONDAY 19 SEPTEMBER 2022

08:00-08:30	MORNING COFFEE Sponsored by Daicel Corporation – Actranza lab	
08:30-09:55	PLENARY SESSION 3: VACCINES ON THE HORIZON Sponsored by Sanofi Pasteur SESSION CHAIRS: Shan Lu, <i>UMASS Medical School</i> and Denise Doolan, <i>James Cook University</i>	
08:30-09:00	Inaugural ISV Dr. Stanley A. Plotkin Keynote Lecture The Evolution of Vaccinology and the Utility of Human Challenges (Pre-Recorded) Stanley Plotkin, <i>Vaxxconsult</i> Recipient of the ISV Lifetime Achievement Award	
09:00-09:25	mRNA Vaccines (R)Evolution – Myths and Realities Jean-Francois Toussaint, <i>Sanofi Pasteur, France</i>	
09:25-09:40	Interim Analysis of a Phase 1/2 Randomized Clinical Trial on the Safety, Reactogenicity, and Immunogenicity of a Quadrivalent, mRNA-Based Seasonal Influenza Vaccine (mRNA-1010) in Healthy Adults Raffael Nachbagauer, <i>Moderna, Inc.</i>	
09:40 -09:55	Development of a Flagellin-Adjuvanted Anti-Tauopathy Vaccination Strategy Targeting Pathologic Conformation Joon Haeng Rhee, <i>Chonnam National University</i>	
10:00-10:30	COFFEE BREAK Sponsored by SK Bioscience	
10:30-12:20	CONCURRENT SESSION 1 COVID-19 VACCINES PART 2 SESSION CHAIRS: Neil Almond, <i>NIBSC</i> Eui-Cheol Shin, <i>KAIST</i>	CONCURRENT SESSION 2 GLOBAL HEALTH AND VACCINES SESSION CHAIRS: Stephen Kent, <i>University of Melbourne</i> Ann Ginsberg, <i>Bill & Melinda Gates Foundation</i>
10:30 -10:55	SARS-CoV-2 Biology and Countermeasure Development Pei-Yong Shi, <i>University of Texas Medical Branch (UTMB)</i>	The mRNA Hub Technology Transfer Programme: Creating a Sustainable Platform for Vaccine Innovation in LMICs Petro Terblanche, <i>Afrigen Biologics & Vaccines</i>
10:55-11:20	Development of a SARS-CoV-2 Vaccine Candidate Using the Papaya Mosaic Virus (PapMV) Nanoparticle Vaccine Platform Denis Leclerc, <i>Université Laval</i>	Strategies for Industrial Production of mRNA Vaccines in South America Analia Acebal, <i>Sinergium Biotech</i>
11:20-11:35	ACM Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine Jiang Hang Lam, <i>ACM Biolabs Pte Ltd</i>	Progress of Clinical Development of a Live-Attenuated Single Shot Chikungunya Vaccine Candidate Susanne Eder-Lingelbach, <i>Valneva Austria</i>
11:35-11:50	An Exosome-Based Pan Beta Coronavirus Vaccine Zhilin Chen, <i>Codiak BioSciences</i>	T Cell Vaccines Against Zika Virus Branka Grubor-Bauk, <i>University of Adelaide</i>
11:50-12:05	A Protein/Peptide Vaccine UB-612 Elicits Broadly Neutralizing Antibodies Against Multiple Variants and Protects Mice and Non-Human Primates Against SARS-CoV-2 Shixia Wang, <i>Vaxxinity Inc.</i>	Immunogenicity and Efficacy in Rodents and Non-Human Primates of a Pair of Two Live-Attenuated Flavivirus-Vectored Vaccine Candidates with Dual Rabies/Yellow Fever, or Rabies/Japanese Encephalitis Activity Lorena Sanchez Felipe, <i>KU Leuven</i>
12:05-12:20	Intranasal Administration of a Live-Attenuated Recombinant Newcastle Disease Virus Expressing the SARS-CoV-2 Spike Protein Induces High Neutralizing Antibody Levels and Protects from Experimental SARS-CoV-2 Infection in Hamsters Nora Gerhards, <i>Wageningen Bioveterinary Research</i>	Toward the Development of a Next-Generation Pre-Emptive SARS-CoV-2 Vaccine Jeffrey Ulmer, <i>TechImmune LLC</i>
12:30-13:30	LUNCH Sponsored by NRC Canada & Merck	
13:30-14:00	MONKEYPOX ROUNDTABLE DISCUSSION (ROOM 308A) Gary Kobinger, <i>UTMB</i> ; Inger Damon, <i>CDC-Retired</i> ; David Weiner, <i>The Wistar Institute</i>	
14:00-15:00	ISV ANNUAL GENERAL MEETING (OPEN TO ALL CONGRESS ATTENDEES-ROOM 308A)	

14:30-15:30	POSTER SESSION # 2
15:00-15:30	COFFEE BREAK Sponsored by BioNTech
15:30-17:35	PLENARY SESSION 4: VACCINE DEVELOPMENT & BIOMANUFACTURING LANDSCAPE IN CANADA SESSION CHAIRS: Lakshmi Krishnan, NRC and Gary Kobinger, UTMB
15:30-15:35	Session Introduction Lakshmi Krishnan, <i>National Research Council Canada</i>
15:35-16:00	Development of a Plant-Based Virus-Like Particle Vaccine Against COVID-19 Marc-André D'Aoust, <i>Medicago</i>
16:00-16:25	Canadian COVID-19 Vaccine Candidates and Programs - Experience of the Clinical Trials Network of the Canadian Immunization Research Network Joanne Langley, <i>Dalhousie University</i>
16:25-16:50	Elephants Can Dance: Health Canada's Regulatory Work For COVID-19 Vaccines Co Pham, <i>Health Canada</i>
16:50-17:05	A DNA Vaccine Against Hyalomma Tick Infestation Protects Sheep Against Multiple Human Tick-Borne Viruses Hugues Fausther-Bovendo, <i>Global Urgent and Advanced Research and Development (GUARD)</i>
17:05-17:20	Breast Cancer Immunopeptidomes Reveal a Large Number of Targetable Tumor Antigens Eralda Kina, <i>University of Montreal</i>
17:20-17:35	Insights from Industry Collaboration in COVID-19 Vaccine Pharmacovigilance- One Manufacturer's Experience" Jamie Wilkins and Susan Mather, <i>Pfizer, Inc.</i>
18:30-22:00	GALA DINNER Sponsored by AstraZeneca *TICKETS REQUIRED*

Continue to Next Page

TUESDAY 20 SEPTEMBER 2022

08:00-09:00	MORNING COFFEE		Sponsored by Pfizer
08:15-09:00	EDUCATIONAL BREAKOUT SESSION MODERATOR: Manon Cox, <i>NextWaveBio</i> PANELISTS: Dan Adams, <i>NextWaveBio</i> ; Margaret Liu, <i>ProTherImmune</i> ; Peter Leonardi, <i>Omnicyte</i>		
09:00-10:20	PLENARY SESSION 5: VACCINES AND ANIMALS SESSION CHAIRS: Connie Schmaljohn, <i>NIAID</i> and Ed Lavelle, <i>Trinity College</i>		
09:00-09:25	Vaccination for the Prevention and Control of Emerging Infectious Diseases in Animals Mahesh Kumar, <i>Zoetis</i>		
Pre-Recorded	100 Days Mission for Vaccines to the World: Disruptive Innovation from Molecule to Ethics Ken Ishii, <i>The University of Tokyo</i>		
09:50-10:05	Next Generation Monkeypox Vaccine Based on Development of an Efficacious T Cell-Directed Smallpox Vaccine Using a Genomes-to-Vaccine Strategy Anne De Groot, <i>EpiVax, Inc.</i>		
10:05-10:20	mRNA Vaccines Against Andes Virus: Comparison of Modified Versus Non-Modified Nucleoside-Based Platforms Alexander Bukreyev, <i>University of Texas Medical Branch (UTMB)</i>		
10:30-11:00	COFFEE BREAK		Sponsored by CanSino Bio
11:00-12:25	CONCURRENT SESSION 3 HIV VACCINES SESSION CHAIRS: Lars Frelin, <i>Karolinska Institutet</i> Petro Terblanche, <i>Afrigen Biologics & Vaccines</i>	CONCURRENT SESSION 4 MANUFACTURING AND EVALUATION SESSION CHAIRS: Amy Espeseth, <i>Merck</i> Xavier Saelens, <i>VIB-UGent</i>	
11:00-11:25	Progress with HIV Vaccine Development Shan Lu, <i>UMASS Chan Medical School</i>	Advancing Vectored Vaccine Design and Manufacturing Platforms for Pandemic Preparedness Amine Kamen, <i>McGill University</i>	
11:25-11:40	Elicitation of Cross-Neutralizing Antibodies to the HIV-1 Envelope Glycoprotein Richard Wyatt, <i>The Scripps Research Institute</i>	Anti-NA and -HA Serum Confers Limited Inter-Lineage Cross Protection Against Recent Influenza B Vaccine Strains Xavier Saelens, <i>VIB-UGent Center for Medical Biotechnology</i>	
11:40-11:55	Assessing the Frequency of Naive B Cells Potentially Capable of Producing Broad Neutralizing Antibodies for HIV Flavio Matassoli, <i>VRC, NIAID, National Institutes of Health</i>	Establishing Serological Correlates of Vaccine Protection against Emerging Diseases Using WHO International Standards as Calibrants Neil Almond - <i>Medicines and Healthcare Products Regulatory Agency (NIBSC)</i>	
11:55-12:10	Novel Subunit Vaccines Engineered on an Immune-Activating Platform Technology, First SARS-CoV-2 and Next HIV Peter Leonardi, <i>Omnicyte</i>	Vaccine-Induced Antibodies to Four Distinct Epitopes on gC2 Correlate with Protection from Lethal HSV-2 Challenge in Mice Lauren Hook, <i>University of Pennsylvania Perelman School of Medicine</i>	
12:10-12:25	Pre-Recorded First-in-Human, Germline Targeting HIV Vaccine B Cell Receptor Analysis Adapting 10X Technology Weiwei Wu, <i>NIAID, National Institutes of Health</i>	Highly protective immunity and reduced viral shedding after intranasal vaccination with an OMV based SARS-CoV-2 vaccine Dinja Oosterhoff, <i>Intravacc</i>	
12:30-14:00	LUNCH		Sponsored by Medicago
14:00-14:20	ISV AWARD CEREMONY		
14:20-16:00	PLENARY SESSION 6: FUTURE OF VACCINOLOGY SESSION CHAIR: Manon Cox, <i>Next Wave Bio</i> and Joon Haeng Rhee, <i>Chonnam National University</i>		

14:20-14:45	ISV Paper of the Year Presentation Neutralizing Antibody Vaccine for Pandemic and Pre-Emergent Coronaviruses Kevin Saunders, <i>Duke University</i>
14:45-15:10	Structure-Based Design and Epitope Focusing in the Development of Vaccines Against Sequence-Diverse Pathogens like HIV-1 Peter Kwong, <i>Vaccine Research Center, NIAID, National Institutes of Health</i>
15:10-15:35	Medical Imaging as a Tool for Assessing Pathogenesis in Animals Connie Schmaljohn, <i>NIAID, National Institutes of Health</i>
15:35-16:00	Contribution of T Cell Responses to Vaccine Immunogenicity Jennifer Juno, <i>University of Melbourne</i>
16:00-16:15	CLOSING SESSION & INTRODUCTION TO 2023 CONGRESS Denise Doolan, ISV President, <i>James Cook University</i>

End of In-Person Program

2022 ISV ANNUAL CONGRESS VIRTUAL PROGRAM

ALL PRE-RECORDINGS AVAILABLE ON THE VIRTUAL PLATFORM

Virtual Session 1: Monkeypox Session Chair: Gary Kobinger, *UTMB*

Monkeypox Virus: Biology, Animal Models, Vaccines and Therapeutics

Bernie Moss, *National Institute of Allergy and Infectious Diseases, NIH*

Monkeypox - Unprecedented Reemergence

Inger Damon, *Centers for Disease Control and Prevention*

Global Response to the Monkeypox Virus Emergence of 2022

Rosamund Lewis, *World Health Organization*

Virtual Session 2: Vaccine Update from Asia

Session Chairs: Shan Lu, *UMMS Chan Medical School*; Joon Haeng Rhee, *Chonnam National University*;
Ken Ishii, *University of Tokyo*

Inhaled Covid-19 Vaccine: Robust Humoral, Cellular, and Mucosal Immunologic Response with Superior Safety Profile

Tao Zhu, *CanSino Biologics*

Development of COVID-19 Subunit Vaccine, Based on Novel Nanoparticle Adjuvant Platform

SuHi Jeon, *EuBiologics*

Evolution of SARS-CoV-2

Kei Sato, *University of Tokyo*

Virtual Session 3: Individual Invited Speakers on Diverse Topics

Emerging Zoonotic Viruses: From Bat to Shrew

Linfa Wang, *Duke-National University of Singapore Medical School Singapore*

Immune Correlates Results for the Uhambo and Imbokodo HIV Vaccine Efficacy Trials

Peter Gilbert, *Fred Hutchinson Cancer Research Center*